Amedisys has agreed to pay $43.75 million to settle a securities fraud class action lawsuit shareholders filed against the company and its top execs in 2010 over alleged losses they suffered as a result of the company’s reported scheme to get additional Medicare reimbursement payments.
The Baton Rouge-based hospice and home health services provider has notified the U.S. Securities and Exchange Commission that the agreement, subject to court approval, was reached on Monday. The case is pending the U.S. District Court of the Middle District of Louisiana, but will be dismissed with prejudice per the agreement.
Amedisys says it’s settling the lawsuit to eliminate “uncertainties, risk, distraction and expenses associated with this protracted litigation.” The company notes the settlement is not an admission of any liability in the matter.
Shareholders filed suit against the company in 2010 for allegedly making false or misleading statements about its business, operations and prospects. Citing court documents, The Wall Street Journal reported in April of that year that Amedisys staff had increased their number of home therapy visits to trigger more costly Medicare reimbursements payments. A former Amedisys nurse told the paper the visits were not always medically necessary.
Amedisys paid $150 million to the federal government in 2014 to settle the allegations that it submitted false billings to the Medicare program between 2008 and 2010. It also enter into a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services as part of the settlement, though it admitted to no wrongdoing.
As for the recent settlement, Amedisys will record a pre-tax charge to its net income of $28.75 million for the second quarter of this year, and the company expects the settlement to be paid in the third quarter. Insurance carriers will cover approximately $15 million of the settlement amount.
—Alexandria Burris
